Peptide stack pharmacology — how half-life and mechanism guide combination design

This thread covers the pharmacology of peptide combination protocols in more depth than the Overview piece. The pharmacokinetics of each compound and the mechanism of each compound together drive the protocol design. Done well, this produces protocols that leverage each compound's strengths and mitigate their limitations. Done poorly, this produces protocols where the dosing pattern of one compound undermines the effect of another.

The two design questions every stack should answer.

Are the mechanisms complementary? If two compounds work through the same pathway, combining them is redundant and may produce diminishing returns due to receptor saturation. If two compounds work through different pathways that converge on a related outcome, combining them can produce additive or synergistic effects. The clearest case is GHRH analog + ghrelin mimetic for GH release — the two pathways are different and the combination is synergistic.

Are the half-lives compatible with the dosing pattern? If two compounds have very different half-lives, dosing them on the same schedule will cause one of them to be underused. A long-acting compound dosed weekly and a short-acting compound dosed weekly will produce sustained presence of the long-acting and minimal cumulative exposure of the short-acting.

The synergy categories — what the research suggests.

Pharmacological synergy. Two compounds activating different receptors in the same downstream pathway can produce greater effect than either alone. GHRH analog + ghrelin mimetic for GH release is the classic case. The two pathways converge on pituitary somatotrophs and the combined activation produces a larger GH pulse than either alone.

Mechanism complementarity. Two compounds working through different mechanisms that target the same outcome from different angles. BPC-157 (vascular, growth factors) + TB-500 (cell migration, recruitment) for tissue repair. The combination addresses repair from complementary directions without competing for the same molecular targets.

Pharmacokinetic stacking. A short-acting compound for acute effects combined with a long-acting compound for sustained baseline. CJC-1295-with-DAC (sustained GH baseline elevation) combined with an additional short-acting GHRP for acute pulses on top of that baseline. The pharmacokinetic profiles complement each other rather than overlap.

Side effect mitigation. A protective compound combined with a primary active compound where the protective component reduces a known side effect. Less common in the peptide space than in the small-molecule pharmacology space but appears in some research protocols.

The half-life landscape across stack-relevant peptides.

Knowing the half-lives is essential for protocol design. The half-life data summarized from the per-category threads:

GLP-1 family (long half-lives): semaglutide 7 days, tirzepatide 5 days, retatrutide 6 days. Once-weekly dosing standard.

GH peptide family (mixed): CJC-1295-with-DAC 6-8 days, CJC-1295-without-DAC 30 minutes, ipamorelin 2 hours, GHRP-2 and GHRP-6 15-30 minutes, MK-677 24 hours, tesamorelin 30 minutes.

BPC-157 4-6 hours, TB-500 short plasma half-life with downstream effects persisting days.

Cosmetic family: GHK-Cu short plasma half-life with tissue effects persisting longer, melanotan I and II 30 minutes to 1 hour, PT-141 2 hours.

Cognitive family: Semax and Selank short plasma half-lives with downstream effects persisting days.

How half-life drives dosing pattern in a stack.

A well-designed stack matches dosing frequency to each compound's half-life rather than imposing a single schedule on all compounds.

Example: BPC-157 + TB-500 stack. BPC-157 has a 4-6 hour plasma half-life. TB-500 has a short plasma half-life but downstream effects persist days. Reasonable dosing patterns: BPC-157 daily or twice daily; TB-500 twice weekly. Imposing a single schedule (both daily, both twice weekly) wastes the advantages of one compound or the other.

Example: CJC + ipamorelin stack. CJC-1295-without-DAC has a 30-minute half-life and produces a short GH pulse. Ipamorelin has a 2-hour half-life and produces a longer GH pulse. The combination is dosed together because the synergy on pituitary somatotrophs requires both compounds present at the time of intended GH pulse. Both are typically dosed 2-3 times daily, with the short half-life driving the frequency.

Example: CJC-with-DAC + ipamorelin stack. CJC-1295-with-DAC has a 6-8 day half-life and provides sustained baseline GH elevation. Ipamorelin has a 2-hour half-life and produces acute pulses. Reasonable dosing: CJC-with-DAC weekly; ipamorelin 2-3 times daily on top of the sustained CJC baseline. The CJC provides the floor, the ipamorelin provides the pulses.

The GH stacking design space — illustrative.

The growth hormone peptide family has the most-developed stacking design space in the research literature, so it makes a useful illustration.

Goal: pulsatile GH release mimicking natural physiology. Use Mod GRF 1-29 + ipamorelin dosed 2-3 times daily. Both short half-lives. Pulsatile pattern matches what natural sleep-onset GH pulses look like.

Goal: sustained GH baseline elevation. Use CJC-1295-with-DAC weekly. Single long-acting compound. Steady-state plasma elevation provides continuous baseline.

Goal: pulsatile pulses on top of sustained baseline. CJC-with-DAC weekly + ipamorelin 2-3 times daily. The combination of pharmacokinetic profiles provides both effects.

Goal: maximum GH release for short-term research questions. GHRH analog + ghrelin mimetic + insulin or other potentiating intervention for acute GH studies. Short-term and not appropriate for sustained protocols.

The cross-category combinations.

Some of the most-discussed combinations on the platform cross category boundaries.

GLP-1 + GH peptides for body recomposition. Combines fat loss from GLP-1 effects with lean mass support from GH-mediated effects. Half-life mismatch is large (GLP-1 weekly, GH peptides multiple times daily) but the mechanisms operate on different time scales so the protocol design works. The cross-category recomp thread covers this in detail.

Recovery stack across BPC-157 + TB-500 + GHK-Cu + ipamorelin. Three compounds for tissue repair (different mechanisms — vascular, cellular migration, copper-mediated remodeling) plus one for systemic recovery support. Half-life and dosing patterns differ across the four; the protocol assigns each its own appropriate frequency.

Why the kitchen-sink approach fails.

Combining many compounds without clear rationale for each tends to fail for several reasons. The mechanisms may not actually complement each other (and may compete for the same molecular targets). The half-life mismatches make it impossible to dose each compound appropriately. The combined side effect profiles become unpredictable. Most importantly, the research output is uninterpretable — if a 6-compound protocol produces an observed effect, it is impossible to attribute the effect to any specific component.

A focused 2-3 compound combination with each compound chosen for a specific mechanism reason and dosed appropriately for its pharmacokinetics produces interpretable research and is the standard approach in well-designed studies.

Practical takeaway.

The mechanism and half-life of each compound drive the stack design. Synergy comes from pathway complementarity, not from compound count. Different half-lives require different dosing frequencies within the same protocol. Cross-category combinations work when each compound's individual pharmacology is respected. Kitchen-sink stacks fail because they ignore both mechanism and pharmacokinetics.

If you want to go deeper into specific stack examples, the related threads in this category cover them — the recovery stack thread, the healing stack thread, the GLP-1 + GH recomp thread, and the cycling thread. The Quality + COA thread covers how to verify every compound in a multi-peptide protocol. The Red Flags thread covers the kitchen-sink and pre-mixed scam patterns.